Novartis Gene Therapies

Novartis Gene Therapies (formerly AveXis) is reimagining medicine to transform the lives of people living with rare genetic diseases. Utilizing cutting-edge technology, we are working to turn promising gene therapies into proven treatments, beginning with our transformative gene therapy for spinal muscular atrophy (SMA). This therapy is now approved in the U.S., Japan, EU and Brazil, and additional registrations are being pursued in close to three dozen countries, with regulatory decisions anticipated in Switzerland, Canada, Australia, Argentina and South Korea in late 2020 or early 2021. Our robust AAV-based pipeline is advancing treatments for Rett syndrome; a genetic form of amyotrophic lateral sclerosis (ALS) caused by mutations in the superoxide dismutase 1 (SOD1) gene; and Friedreich’s ataxia. We are powered by the world’s largest gene therapy manufacturing footprint of more than one million square feet, enabling us to bring gene therapy to patients around the world at quality and scale.Read Our Community Guidelines: https://bit.ly/2V4AjC5 How to reach us:Novartis Gene Therapies2275 Half Day Road, Suite 200Bannockburn, IL 60015Email: [email protected] Phone: 847.572.8280Toll-free Phone: 844.4.AVEXIS (844.428.3947)